Novartis AG Website

Novartis AG

SWX-NOVN

Company Overview

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

  • Name

    Novartis AG

  • CEO

    Vasant Narasimhan

  • Website

    www.novartis.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1996

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Novartis' research and development focuses on therapeutic areas that have historically been amenable to commercial innovation, including oncology, immunology, rare diseases, and cardiovascular.

  • The company has a plethora of growth drivers in its commercial portfolio, including neurology drug Kesimpta, cardiovascular drug Leqvio, cancer drugs Kisqali, Pluvicto, and Scemblix, and rare immunology drug Fabhalta.

  • Novartis continues to invest heavily in pipeline innovation, including radioligand cancer therapies, B-cell mediated immunology, and drugs that reduce cardiovascular risks.

Bears Say

  • The company is undergoing declines in older drugs, including Entresto, Tasigna, and Promacta/Revolade.

  • The company will need more progress in its immunology portfolio over the next five years to offset Cosentyx's loss of exclusivity, which we expect to occur around 2029 or so for the US market.

  • Novartis is not as active in immuno-oncology, which may hurt its overall cancer presence given the potential that this class of drugs has for combination therapies.

Source: Morningstar Analysis - Oct 29, 2025

What's happening

Nov 6, 2025 - Dec 6, 2025

Novartis AG Surges on FDA Approval and Analyst Upgrades

  • Novartis AG received FDA approval for Itvisma, the first gene-replacement therapy for spinal muscular atrophy across all age groups.
  • Morgan Stanley upgraded Novartis to "Overweight," boosting investor confidence following strong quarterly results.
  • The company announced expansion plans in North Carolina while facing concerns about workforce reductions and generic competition.

Over the past month, Novartis AG (NVS) experienced a notable overall movement of 5.4%, significantly outperforming the S&P 500's return of 1.2%. This performance reflects a robust market response to key developments within the company, particularly its innovative therapies and strategic upgrades from analysts. A pivotal moment occurred when NVS received FDA approval for Itvisma, marking it as the first gene-replacement therapy applicable across all age groups for spinal muscular atrophy. This breakthrough showcased Novartis's commitment to advancing healthcare and positively influenced stock sentiment.

Additionally, an upgrade by Morgan Stanley to "Overweight" further bolstered investor confidence regarding NVS's future prospects. This upgrade coincided with strong quarterly results that highlighted increases in revenue and free cash flow, reinforcing expectations for high single-digit sales growth moving forward. Positive trial outcomes for KLU156 (GanLum), a new malaria treatment demonstrating exceptional efficacy against resistant strains, also played a crucial role in enhancing NVS’s market position.

Despite these bullish trends, some bearish signals impacted NVS during this period. Reports of workforce reductions due to shifts in manufacturing priorities raised concerns about operational efficiency and long-term strategy execution. Speculation surrounding potential increases in acquisition bids added uncertainty among investors regarding management decisions and their implications on future growth trajectories.

The company's expansion plans into North Carolina represent another significant investment aimed at strengthening U.S.-based operations while creating new jobs over the next few years; however, this initiative came amid mixed sentiments about ongoing challenges related to generic competition affecting key drugs within its portfolio. Overall, while certain events introduced volatility into NVS’s stock performance—such as management changes or strategic adjustments—the overarching narrative remained positive due to substantial advancements in product offerings and favorable analyst ratings.

Novartis AG outperformed both the Health Care sector by 0.2% and the broader S&P 500 index over this one-month period through strategic innovations and positive financial indicators despite facing some operational challenges along the way.

SWX:NOVN